Abstract |
CAUSAL AGENTS: Several Borrelia burgdorferi sensu lato species have been recently described which cause different clinical forms of Lyme disease. B. garinii is implicated in neurological forms, B. burgdorferi sensu stricto in articular forms and B. afzelii in late cutaneous forms. As such disease diversity is seen only in Europe and Asia, clinical management in Europe is somewhat different than in North America. NUMEROUS CLINICAL TRIALS: A recently proposed classification of the European forms of Lyme disease is based on clinical presentation: contagious conditions or erythema migrans, early neurologic or cardiologic complications, late articular, neurologic or cutaneous complications. Therapeutic proposals should be guided by the results of European trials, taking into account this classification. ADAPTED MANAGEMENT:
|
Authors | R Dhôte, A L Basse-Guerineau, C Bachmeyer, B Christoforov, M V Assous |
Journal | Presse medicale (Paris, France : 1983)
(Presse Med)
Vol. 27
Issue 39
Pg. 2043-7
(Dec 12 1998)
ISSN: 0755-4982 [Print] France |
Vernacular Title | Borrélioses de Lyme: aspects thérapeutiques. |
PMID | 9893696
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Cephalosporins
- Macrolides
- Penicillins
- Amoxicillin
- Doxycycline
|
Topics |
- Amoxicillin
- Anti-Bacterial Agents
(pharmacology, therapeutic use)
- Borrelia burgdorferi Group
(drug effects)
- Cephalosporins
- Doxycycline
(therapeutic use)
- Humans
- Lyme Disease
(drug therapy, microbiology)
- Macrolides
- Penicillins
(therapeutic use)
|